Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants

BACKGROUND: The Omicron variant of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) was identified in Japan in November 2021. This variant contains up to 36 mutations in the spike protein, the target of neutralizing antibodies, and can escape vaccine-induced immunity. A booster vaccinati...

Descripción completa

Detalles Bibliográficos
Autores principales: Seki, Yohei, Yoshihara, Yasuo, Nojima, Kiyoko, Momose, Haruka, Fukushi, Shuetsu, Moriyama, Saya, Wagatsuma, Ayumi, Numata, Narumi, Sasaki, Kyohei, Kuzuoka, Tomoyo, Yato, Yoshiyuki, Takahashi, Yoshimasa, Maeda, Ken, Suzuki, Tadaki, Mizukami, Takuo, Hamaguchi, Isao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2022
Materias:
Clinical and Translational Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040508/
https://www.ncbi.nlm.nih.gov/pubmed/35815933
http://dx.doi.org/10.1016/j.medj.2022.04.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9040508/
https://www.ncbi.nlm.nih.gov/pubmed/35815933
http://dx.doi.org/10.1016/j.medj.2022.04.013

Ejemplares similares